Abbott Laboratories, US0028241000

Abbott Laboratories stock: Quote update after pipeline report

Published on 11/16/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock traded at 99.78 euros on Lang & Schwarz on Monday, November 16, at 16:08 CET. Recent device and diagnostics developments remain the business backdrop for investors.

Pipeline updates remain in focus

  • Abbott announced new diagnostic and cardiac-device developments on November 10.
  • The Panbio home test expands respiratory testing in Canada, while the UltiSynq lead adds a cardiac-device milestone.
  • Investors are watching how the product pipeline translates into commercial growth.
Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories stock traded at 99.78 euros on Lang & Schwarz at 16:08 CET on Monday, November 16, 2026. The quote compares with 98.48 euros in the Abbott article published on November 14, a difference of 1.32 percent since that publication.

The latest market context includes product announcements from November 10. A Longbridge weekly review reported that Abbott launched its Panbio COVID-19 and flu A/B self-test in Canada and announced FDA approval and CE marking for an implantable cardioverter-defibrillator lead.

Recent pipeline developments

The Panbio test targets at-home detection of COVID-19 and influenza A and B. The review said the product was being rolled out through more than 1,800 Canadian pharmacies, giving the diagnostics portfolio a broader consumer reach.

The UltiSynq lead is designed to support conduction-system pacing and defibrillation. For investors, the two announcements point to different commercial profiles: a consumer diagnostic product with pharmacy distribution and a regulated cardiac device aimed at specialist care.

What investors watch next

Abbott's pipeline remains central to the investment case alongside the company's established medical-device, diagnostics and nutrition businesses. The near-term question is how quickly new approvals and launches contribute to revenue and offset pressure in slower-growth areas.

The broader US healthcare market context is available in Current market reports.

More news and analyses on Abbott Laboratories stock.

Abbott Laboratories overview

  • Company: Abbott Laboratories
  • ISIN: US0028241000
  • US ticker: ABT
  • Quoted price: 99.78 euros on Lang & Schwarz, November 16, 2026, 16:08 CET
Disclaimer...
en | US0028241000 | ABBOTT LABORATORIES | boerse | 70521502 | bgmi